![Validation of the GRade, Age, Nodes and Tumor (GRANT) score within the Surveillance Epidemiology and End Results (SEER) database: A new tool to predict survival in surgically treated renal cell carcinoma patients Validation of the GRade, Age, Nodes and Tumor (GRANT) score within the Surveillance Epidemiology and End Results (SEER) database: A new tool to predict survival in surgically treated renal cell carcinoma patients](https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41598-019-49250-6/MediaObjects/41598_2019_49250_Fig2_HTML.png)
Validation of the GRade, Age, Nodes and Tumor (GRANT) score within the Surveillance Epidemiology and End Results (SEER) database: A new tool to predict survival in surgically treated renal cell carcinoma patients
![Survival after complete surgical resection of multiple metastases from renal cell carcinoma - Alt - 2011 - Cancer - Wiley Online Library Survival after complete surgical resection of multiple metastases from renal cell carcinoma - Alt - 2011 - Cancer - Wiley Online Library](https://acsjournals.onlinelibrary.wiley.com/cms/asset/915d787e-fafa-4509-ba32-6b53e5c696de/mfig005.jpg)
Survival after complete surgical resection of multiple metastases from renal cell carcinoma - Alt - 2011 - Cancer - Wiley Online Library
![Duration of First-line Treatment with Molecular Targeted-Therapy Is a Prognostic Factor in Metastatic Renal Cell Carcinoma | Anticancer Research Duration of First-line Treatment with Molecular Targeted-Therapy Is a Prognostic Factor in Metastatic Renal Cell Carcinoma | Anticancer Research](https://ar.iiarjournals.org/content/anticanres/35/6/3415/F2.large.jpg)
Duration of First-line Treatment with Molecular Targeted-Therapy Is a Prognostic Factor in Metastatic Renal Cell Carcinoma | Anticancer Research
![Survival of patients receiving systematic therapy for metachronous or synchronous metastatic renal cell carcinoma: a retrospective analysis | BMC Cancer | Full Text Survival of patients receiving systematic therapy for metachronous or synchronous metastatic renal cell carcinoma: a retrospective analysis | BMC Cancer | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs12885-019-5900-1/MediaObjects/12885_2019_5900_Fig4_HTML.png)
Survival of patients receiving systematic therapy for metachronous or synchronous metastatic renal cell carcinoma: a retrospective analysis | BMC Cancer | Full Text
![Overall survival of 180 patients with metastatic renal cell carcinoma... | Download Scientific Diagram Overall survival of 180 patients with metastatic renal cell carcinoma... | Download Scientific Diagram](https://www.researchgate.net/publication/301480827/figure/fig1/AS:485970496757760@1492875803905/Overall-survival-of-180-patients-with-metastatic-renal-cell-carcinoma-treated-with-IFN-a.png)
Overall survival of 180 patients with metastatic renal cell carcinoma... | Download Scientific Diagram
![Overall survival for patients with progressive metastatic renal cell... | Download Scientific Diagram Overall survival for patients with progressive metastatic renal cell... | Download Scientific Diagram](https://www.researchgate.net/publication/7781128/figure/fig2/AS:601588360032308@1520441250678/Overall-survival-for-patients-with-progressive-metastatic-renal-cell-carcinoma-treated.png)
Overall survival for patients with progressive metastatic renal cell... | Download Scientific Diagram
![The number of metabolic features as a significant prognostic factor in patients with metastatic renal cell carcinoma | Scientific Reports The number of metabolic features as a significant prognostic factor in patients with metastatic renal cell carcinoma | Scientific Reports](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41598-020-63816-9/MediaObjects/41598_2020_63816_Fig1_HTML.png)
The number of metabolic features as a significant prognostic factor in patients with metastatic renal cell carcinoma | Scientific Reports
![Renal Cell Carcinoma in Adults 40 Years Old or Less: Young Age is an Independent Prognostic Factor for Cancer-Specific Survival - European Urology Renal Cell Carcinoma in Adults 40 Years Old or Less: Young Age is an Independent Prognostic Factor for Cancer-Specific Survival - European Urology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/c13539ab-0277-4429-bb72-b18d3730bbca/gr1.jpg)
Renal Cell Carcinoma in Adults 40 Years Old or Less: Young Age is an Independent Prognostic Factor for Cancer-Specific Survival - European Urology
![Frontiers | Retrospective Multicenter Long-Term Follow-up Analysis of Prognostic Risk Factors for Recurrence-Free, Metastasis-Free, Cancer-Specific, and Overall Survival After Curative Nephrectomy in Non-metastatic Renal Cell Carcinoma Frontiers | Retrospective Multicenter Long-Term Follow-up Analysis of Prognostic Risk Factors for Recurrence-Free, Metastasis-Free, Cancer-Specific, and Overall Survival After Curative Nephrectomy in Non-metastatic Renal Cell Carcinoma](https://www.frontiersin.org/files/MyHome%20Article%20Library/473816/473816_Thumb_400.jpg)
Frontiers | Retrospective Multicenter Long-Term Follow-up Analysis of Prognostic Risk Factors for Recurrence-Free, Metastasis-Free, Cancer-Specific, and Overall Survival After Curative Nephrectomy in Non-metastatic Renal Cell Carcinoma
![Survival of patients receiving systematic therapy for metachronous or synchronous metastatic renal cell carcinoma: a retrospective analysis | BMC Cancer | Full Text Survival of patients receiving systematic therapy for metachronous or synchronous metastatic renal cell carcinoma: a retrospective analysis | BMC Cancer | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs12885-019-5900-1/MediaObjects/12885_2019_5900_Fig2_HTML.png)
Survival of patients receiving systematic therapy for metachronous or synchronous metastatic renal cell carcinoma: a retrospective analysis | BMC Cancer | Full Text
![Nivolumab plus ipilimumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial | Nature Medicine Nivolumab plus ipilimumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial | Nature Medicine](https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41591-022-01694-6/MediaObjects/41591_2022_1694_Fig1_HTML.png)
Nivolumab plus ipilimumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial | Nature Medicine
![The Clinicopathological features and survival outcomes of patients with different metastatic sites in stage IV breast cancer | BMC Cancer | Full Text The Clinicopathological features and survival outcomes of patients with different metastatic sites in stage IV breast cancer | BMC Cancer | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs12885-019-6311-z/MediaObjects/12885_2019_6311_Fig3_HTML.png)
The Clinicopathological features and survival outcomes of patients with different metastatic sites in stage IV breast cancer | BMC Cancer | Full Text
![Overall survival curves for (A) all 140 patients with metastatic renal... | Download Scientific Diagram Overall survival curves for (A) all 140 patients with metastatic renal... | Download Scientific Diagram](https://www.researchgate.net/profile/Jun-Teishima/publication/263702696/figure/fig2/AS:667619061411855@1536184196912/Overall-survival-curves-for-A-all-140-patients-with-metastatic-renal-cell-carcinoma-and.png)
Overall survival curves for (A) all 140 patients with metastatic renal... | Download Scientific Diagram
![Treatment patterns and clinical outcomes in patients with renal cell carcinoma in the UK: insights from the RECCORD registry - ScienceDirect Treatment patterns and clinical outcomes in patients with renal cell carcinoma in the UK: insights from the RECCORD registry - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0923753419353566-gr1.jpg)
Treatment patterns and clinical outcomes in patients with renal cell carcinoma in the UK: insights from the RECCORD registry - ScienceDirect
![Primary Tumor Shrinkage and the Effect on Metastatic Disease and Outcomes in Patients With Advanced Kidney Cancer With Intermediate or Poor Prognosis Treated With Nivolumab Plus Ipilimumab or Cabozantinib - Clinical Genitourinary Primary Tumor Shrinkage and the Effect on Metastatic Disease and Outcomes in Patients With Advanced Kidney Cancer With Intermediate or Poor Prognosis Treated With Nivolumab Plus Ipilimumab or Cabozantinib - Clinical Genitourinary](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/04f3cd1a-7ada-455e-84a4-4f0f15bcbde5/gr1_lrg.jpg)
Primary Tumor Shrinkage and the Effect on Metastatic Disease and Outcomes in Patients With Advanced Kidney Cancer With Intermediate or Poor Prognosis Treated With Nivolumab Plus Ipilimumab or Cabozantinib - Clinical Genitourinary
![Survival of patients receiving systematic therapy for metachronous or synchronous metastatic renal cell carcinoma: a retrospective analysis | BMC Cancer | Full Text Survival of patients receiving systematic therapy for metachronous or synchronous metastatic renal cell carcinoma: a retrospective analysis | BMC Cancer | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs12885-019-5900-1/MediaObjects/12885_2019_5900_Fig1_HTML.png)
Survival of patients receiving systematic therapy for metachronous or synchronous metastatic renal cell carcinoma: a retrospective analysis | BMC Cancer | Full Text
![Real-World Data from a Metastatic Renal Cell Carcinoma Community-Academic Registry: Comparative Outcomes of Progression Free Survival and Overall Survival - IOS Press Real-World Data from a Metastatic Renal Cell Carcinoma Community-Academic Registry: Comparative Outcomes of Progression Free Survival and Overall Survival - IOS Press](https://content.iospress.com/media/kca/2019/3-2/kca-3-2-kca190059/kca-3-kca190059-g003.jpg?width=755)
Real-World Data from a Metastatic Renal Cell Carcinoma Community-Academic Registry: Comparative Outcomes of Progression Free Survival and Overall Survival - IOS Press
![Frontiers | Cause-Specific Mortality Among Survivors From T1N0M0 Renal Cell Carcinoma: A Registry-Based Cohort Study Frontiers | Cause-Specific Mortality Among Survivors From T1N0M0 Renal Cell Carcinoma: A Registry-Based Cohort Study](https://www.frontiersin.org/files/Articles/604724/fonc-11-604724-HTML/image_m/fonc-11-604724-g001.jpg)